Mesintel Therapeutics
San Diego, United States· Est.
A biotech platform focused on fibroblast biology to create next‑generation therapies for high‑unmet‑need diseases.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Funding information not available
AI Company Overview
A biotech platform focused on fibroblast biology to create next‑generation therapies for high‑unmet‑need diseases.
OncologyFibrosisRare DiseasesRegenerative MedicineAging
Technology Platform
Proprietary fibroblast target discovery platform that integrates single‑cell multi‑omics, functional genomics, cellular lineage tracing, and AI/ML to identify disease‑modifying fibroblast targets.
Opportunities
Leveraging a unique fibroblast‑centric platform to develop first‑in‑class therapeutics for oncology, fibrosis and regenerative indications, with potential for strategic partnerships and out‑licensing.
Risk Factors
Early‑stage company with no disclosed clinical candidates; scientific validation and regulatory pathways remain uncertain.
Competitive Landscape
Few competitors focus specifically on fibroblast biology; Mesintel differentiates through its multi‑omics/AI integration but must demonstrate translational success against established oncology and fibrosis players.